A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus

Z. W. Chaudhry, R. S. Doshi, A. K. Mehta, D. K. Jacobs, R. M. Vakil, Clare Lee, Sara N Bleich, Rita R. Kalyani, Jeanne Clark, Kimberly A Gudzune

Research output: Contribution to journalReview article

Abstract

Objective: We examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM). Methods: We searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose. Results: We included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4% more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3% more than counselling at 6 months, and OPTIFAST reduced A1c 0.3% more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions. Discussion: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions.

Original languageEnglish (US)
Pages (from-to)758-769
Number of pages12
JournalObesity Reviews
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Weight Reduction Programs
Type 2 Diabetes Mellitus
Counseling
Randomized Controlled Trials
Population Characteristics
MEDLINE
Hemoglobins
Databases
Education
Glucose
Population

Keywords

  • Commercial weight loss
  • glucose
  • haemoglobin A1c
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Endocrinology, Diabetes and Metabolism

Cite this

A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. / Chaudhry, Z. W.; Doshi, R. S.; Mehta, A. K.; Jacobs, D. K.; Vakil, R. M.; Lee, Clare; Bleich, Sara N; Kalyani, Rita R.; Clark, Jeanne; Gudzune, Kimberly A.

In: Obesity Reviews, Vol. 17, No. 8, 01.08.2016, p. 758-769.

Research output: Contribution to journalReview article

@article{e5eb274110104a358e0eb1ec8d8d58e9,
title = "A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus",
abstract = "Objective: We examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM). Methods: We searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose. Results: We included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4{\%} more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3{\%} more than counselling at 6 months, and OPTIFAST reduced A1c 0.3{\%} more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions. Discussion: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions.",
keywords = "Commercial weight loss, glucose, haemoglobin A1c, type 2 diabetes mellitus",
author = "Chaudhry, {Z. W.} and Doshi, {R. S.} and Mehta, {A. K.} and Jacobs, {D. K.} and Vakil, {R. M.} and Clare Lee and Bleich, {Sara N} and Kalyani, {Rita R.} and Jeanne Clark and Gudzune, {Kimberly A}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/obr.12423",
language = "English (US)",
volume = "17",
pages = "758--769",
journal = "Obesity Reviews",
issn = "1467-7881",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus

AU - Chaudhry, Z. W.

AU - Doshi, R. S.

AU - Mehta, A. K.

AU - Jacobs, D. K.

AU - Vakil, R. M.

AU - Lee, Clare

AU - Bleich, Sara N

AU - Kalyani, Rita R.

AU - Clark, Jeanne

AU - Gudzune, Kimberly A

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objective: We examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM). Methods: We searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose. Results: We included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4% more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3% more than counselling at 6 months, and OPTIFAST reduced A1c 0.3% more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions. Discussion: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions.

AB - Objective: We examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM). Methods: We searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose. Results: We included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4% more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3% more than counselling at 6 months, and OPTIFAST reduced A1c 0.3% more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions. Discussion: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions.

KW - Commercial weight loss

KW - glucose

KW - haemoglobin A1c

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84978863295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978863295&partnerID=8YFLogxK

U2 - 10.1111/obr.12423

DO - 10.1111/obr.12423

M3 - Review article

C2 - 27230990

AN - SCOPUS:84978863295

VL - 17

SP - 758

EP - 769

JO - Obesity Reviews

JF - Obesity Reviews

SN - 1467-7881

IS - 8

ER -